GLENMARK 
Glenmark Pharmaceuticals Ltd
How do you think glenmark will perform against the NIFTY? Pick this stock
CAPITAL4 COMMUNITY
All: Members who that have picked this stock: 74
68 outperforms
6 underperforms
Stars: Top Investors who have picked this stock: 0
0 outperforms
0 underperforms
CLASSIFICATION | SECTOR | INDUSTRY |
|---|---|---|
| Primary | Pharma & Healthcare | Pharmaceuticals |
SNAPSHOT
- BSE Code / NSE Ticker
- 532296 / GLENMARK
- Last traded time
- 2012-05-23 15:59:09
- Last traded on
- BSE
- Intra-day Low / High
- 345.0 / 359.4
- 52w closing Low / High
- 272.1 / 365.4
- Today Volume
- 940,179
- 30d avg Daily Volume
- 1,056,128
- Market Cap
- INR 9,628.4 cr
- P/E Ratio TTM
- 36.28
- Historical Performance
- Today
- Weekly
- Monthly
- 3 Months
- 1 Year
- -0.3%
- 2.3%
- 10.0%
- 14.7%
- 24.8%
valuation snapshotpeer comparisonfinancialsshare holdingmf holdingcommunity picksbrokerage picks
Industry: Pharmaceuticals
| Parameter++ Click on Parameter for definition | Value | Industry Median | Industry Weighted Avg | Parameter ++ | Per Share Value | |
|---|---|---|---|---|---|---|
| Gross Margin | 52.4% | 20.2% | 30.9% | Last Closing Price | 355.95 | |
| Core Operating Margin | 22.4% | 6.1% | 12.2% | Book Value per share | 73.37 | |
| EBIT Margin | 28.0% | 10.8% | 41.2% | Long-term Debt per share | 42.48 | |
| Net Profit Margin | 17.7% | 5.1% | 30.3% | Enterprise Value per share | 400.36 | |
| Adj Net Profit Margin | 17.7% | 5.0% | 14.4% | Net Cash per share | 0.96 | |
| Return on Assets | 6.8% | 5.5% | 21.2% | Cash from Operations per share | 15.60 | |
| Return on Capital Employed | 10.9% | 12.2% | 30.9% | Free Cashflow per share | 13.86 | |
| Return on Equity | 10.7% | 9.2% | 30.7% | Sales per share | 44.52 | |
| Asset Turnover | 0.38 | 0.97 | 0.70 | Total income per share | 47.01 | |
| Cash Return (FCFF/EV) | 4.1% | -40.4% | 0.3% | PAT per share | 7.86 | |
| Adj Price-to-Earnings TTM ** | 36.39 | 26.06 | -- | Adj PAT per share | 7.86 | |
| Adj Price-to-Earnings | 45.51 | 17.15 | 25.44 | |||
| Price-to-Book | 4.88 | 1.23 | 3.71 | |||
| Price-to-FCF | 25.82 | -- | -846.96 | |||
| EV / EBITDA | 30.21 | 9.34 | 9.23 | |||
| Price-to-Sales | 8.04 | 0.76 | 3.67 | |||
| Financial Leverage | 1.58 | 1.46 | 1.45 | |||
| Interest Coverage | 3.92 | 4.51 | 14.57 | |||
| Debt to MarketCap | 0.12 | 0.33 | 0.12 | |||
| 1y Dividend Yield | 0.1% | 0.2% | 1.0% | |||
| 1y Dividend Payout | 5.1% | 3.4% | 24.3% | |||
| 3y Dividend Yield | 0.1% | 0.6% | 0.8% | |||
| 3y Dividend Payout | 5.7% | 9.4% | 25.0% | |||
| 3y Sales Growth CAGR | -4.3% | 13.7% | 12.9% | |||
| 3y Earnings Growth CAGR | -18.3% | 0.6% | 39.7% |
++ All values calculated using standalone 2011 Financial Results (unless otherwise mentioned)
** From last 4 quarterly results
CAPITAL4 COMMUNITY
STOCK SCREENERS
INDIA CAPITAL MARKETS
GLENMARK IN THE NEWS
- May-11 10:40 Glenmark Pharmaceuticals allots shares
- May-08 17:06 Glenmark Pharmaceuticals recommends dividend
- May-04 11:30 Glenmark Pharmaceuticals to announce financial results
- Apr-09 10:40 Glenmark Generics receives ANDA approval for Norgestimate and Ethinyl Estradiol tablets
- Apr-03 11:31 Glenmark Generics receives ANDA approval for Desogestrel & Ethinyl Estradiol tablets
- Mar-16 16:28 Glenmark Pharmaceuticals allots equity shares
- Mar-07 10:57 Glenmark Generics receives USFDA approval for Imiquimod Cream
- Mar-01 16:42 Glenmark Generics receives ANDA approvals for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets
- Feb-14 16:58 Glenmark Pharmaceuticals allots shares
- Feb-14 11:28 Glenmark's novel molecule 'GRC 17536' successfully completes Phase I trials in Europe
TOP BLOGS
- Advice for – Tuesday, May 22, 2012
by ABHISHEK-PARAKH
(Recommendations: 6) - Money can be made in all market conditions
by ASHOKSHARMA
(Recommendations: 7) - The problem with historical returns
by ROHIT CHAUHAN
(Recommendations: 9) - Markets: What next?
by Nishit_Vadhavkar
(Recommendations: 8) - Nifty – RSI at sub 30. Highly Oversold – Bottoming out in next few sessions
by NOORESH MERANI
(Recommendations: 9) - Follow up: Gujarat reclaim & rubber products ltd
by ROHIT CHAUHAN
(Recommendations: 9) - Negative news drags the markets down
by Nishit_Vadhavkar
(Recommendations: 7) - Option strategy worked will in such unpredictable market
by ASHOKSHARMA
(Recommendations: 8) - Sensex- Technical Outlook and Trading Levels, 8 April 2012
by D_Sathiamoorthy
(Recommendations: 5) - Insourcing vs. outsourcing government functions: A setback for public sector production of elementary education
by AJAY SHAH
(Recommendations: 7) - Crucial Week Ahead
by Nishit_Vadhavkar
(Recommendations: 8)
Company and Mutual Fund Finder
| Company: | 3ABCDEFGHIJKLMNOPQRSTUVWXYZ |
| Indices: | NIFTY | SENSEX | BSE 100 | BSE 200 | BSE 500 | BSE MIDCAP | BSE SMALLCAP | BSE AUTO | BSE BANKEX | BSE CD | BSE CG | BSE FMCG | BSE HC | BSE IT | BSE METAL | BSE OIL | BSE POWER | BSE PSU | BSE REALTY | BSE TECK | BSE DOLLEX | DOLLEX 100 | DOLLEX 200 | NIFTY JUNIOR | CNX MIDCAP | NIFTY MID50 | BANK NIFTY | CNX IT | CNX100 | CNX 500 | CNX DEFTY |
| Mutual Funds: | AIG Global Investment | AXIS | Baroda Pioneer | Benchmark | Bharti AXA | Birla Sun Life | Canara Robeco | Deutsche | DSP BlackRock | Edelweiss | Escorts | Fidelity | Fortis | Franklin Templeton | HDFC | HSBC | ICICI Prudential | IDBI | IDFC | ING | JM Financial | JP Morgan | Kotak Mahindra | L&T | LIC | Mirae Asset | Morgan Stanley | Motilal Oswal | Peerless | Pramerica | PRINCIPAL | Quantum | Reliance | Religare | Sahara | SBI | Shinsei | Sundaram BNP Paribas | Tata | Taurus | UTI |